世界のがん治療用チェックポイント阻害剤市場予測 2021年-2026年

◆英語タイトル:Global Checkpoint Inhibitors for Treating Cancer Market Growth 2021-2026
◆商品コード:LPI21JL16323
◆発行会社(リサーチ会社):LP Information
◆発行日:2021年7月
◆ページ数:137
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2-3営業日)
◆調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥402,600見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥603,900見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥805,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はLP Information社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
LP Information社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

LPインフォメーション社の「がん治療用チェックポイント阻害剤の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、PD-1阻害剤、PD-L1阻害剤、CTLA-4阻害剤など、用途別には、メラノーマ治療、膀胱がん治療、その他などにセグメント区分してまとめました。がん治療用チェックポイント阻害剤のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。
・がん治療用チェックポイント阻害剤の世界市場概要(サマリー)
・がん治療用チェックポイント阻害剤の企業別販売量・売上
・がん治療用チェックポイント阻害剤の企業別市場シェア
・がん治療用チェックポイント阻害剤の世界市場規模 2016年-2021年:種類別(PD-1阻害剤、PD-L1阻害剤、CTLA-4阻害剤)
・がん治療用チェックポイント阻害剤の世界市場規模 2016年-2021年:用途別(メラノーマ治療、膀胱がん治療、その他)
・がん治療用チェックポイント阻害剤の南北アメリカ市場規模(アメリカ、カナダ、メキシコなど)
・がん治療用チェックポイント阻害剤のアジア市場規模(日本、中国、韓国、インド、東南アジアなど)
・がん治療用チェックポイント阻害剤のヨーロッパ市場規模(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・がん治療用チェックポイント阻害剤の中東・アフリカ市場(エジプト、南アフリカ、トルコ、GCC諸国など)
・がん治療用チェックポイント阻害剤市場の成長要因・課題・動向
・がん治療用チェックポイント阻害剤の世界市場予測 2021年-2026年
・がん治療用チェックポイント阻害剤の南北アメリカ市場予測(アメリカ、カナダ、メキシコなど)
・がん治療用チェックポイント阻害剤のアジア市場予測(日本、中国、韓国、インド、東南アジアなど)
・がん治療用チェックポイント阻害剤のヨーロッパ市場予測(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・がん治療用チェックポイント阻害剤の中東・アフリカ市場予測(エジプト、南アフリカ、トルコ、GCC諸国など)
・がん治療用チェックポイント阻害剤の世界市場予測:種類別(PD-1阻害剤、PD-L1阻害剤、CTLA-4阻害剤)
・がん治療用チェックポイント阻害剤の世界市場予測:用途別(メラノーマ治療、膀胱がん治療、その他)
・主要企業分析
【レポートの概要】

According to this latest study, the 2021 growth of Checkpoint Inhibitors for Treating Cancer will have significant change from previous year. By the most conservative estimates of global Checkpoint Inhibitors for Treating Cancer market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 9430.1 million in 2020. Over the next five years the Checkpoint Inhibitors for Treating Cancer market will register a 26.6% CAGR in terms of revenue, the global market size will reach US$ 24190 million by 2026.

This report presents a comprehensive overview, market shares, and growth opportunities of Checkpoint Inhibitors for Treating Cancer market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Melanoma Treatment
Bladder Cancer Treatment
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
Bristol-Myers Squibb(BMS)
Merck
Roche

【レポートの目次】

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Checkpoint Inhibitors for Treating Cancer Consumption 2016-2026
2.1.2 Checkpoint Inhibitors for Treating Cancer Consumption CAGR by Region
2.2 Checkpoint Inhibitors for Treating Cancer Segment by Type
2.2.1 PD-1 Inhibitors
2.2.2 PD-L1 Inhibitors
2.2.3 CTLA-4 Inhibitors
2.3 Checkpoint Inhibitors for Treating Cancer Sales by Type
2.3.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2016-2021)
2.3.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Type (2016-2021)
2.3.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Type (2016-2021)
2.4 Checkpoint Inhibitors for Treating Cancer Segment by Application
2.4.1 Melanoma Treatment
2.4.2 Bladder Cancer Treatment
2.4.3 Other
2.5 Checkpoint Inhibitors for Treating Cancer Sales by Application
2.5.1 Global Checkpoint Inhibitors for Treating Cancer Sale Market Share by Application (2016-2021)
2.5.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Application (2016-2021)
2.5.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Application (2016-2021)

3 Global Checkpoint Inhibitors for Treating Cancer by Company
3.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company
3.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Company (2019-2021)
3.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company (2019-2021)
3.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Company
3.2.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Company (2019-2021)
3.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Company (2019-2021)
3.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Company
3.4 Global Manufacturers Checkpoint Inhibitors for Treating Cancer Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Checkpoint Inhibitors for Treating Cancer Product Location Distribution
3.4.2 Players Checkpoint Inhibitors for Treating Cancer Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Checkpoint Inhibitors for Treating Cancer by Region
4.1 Global Checkpoint Inhibitors for Treating Cancer by Region
4.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Region
4.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Region
4.2 Americas Checkpoint Inhibitors for Treating Cancer Sales Growth
4.3 APAC Checkpoint Inhibitors for Treating Cancer Sales Growth
4.4 Europe Checkpoint Inhibitors for Treating Cancer Sales Growth
4.5 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Growth

5 Americas
5.1 Americas Checkpoint Inhibitors for Treating Cancer Sales by Country
5.1.1 Americas Checkpoint Inhibitors for Treating Cancer Sales by Country (2016-2021)
5.1.2 Americas Checkpoint Inhibitors for Treating Cancer Revenue by Country (2016-2021)
5.2 Americas Checkpoint Inhibitors for Treating Cancer Sales by Type
5.3 Americas Checkpoint Inhibitors for Treating Cancer Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC Checkpoint Inhibitors for Treating Cancer Sales by Region
6.1.1 APAC Checkpoint Inhibitors for Treating Cancer Sales by Region (2016-2021)
6.1.2 APAC Checkpoint Inhibitors for Treating Cancer Revenue by Region (2016-2021)
6.2 APAC Checkpoint Inhibitors for Treating Cancer Sales by Type
6.3 APAC Checkpoint Inhibitors for Treating Cancer Sales by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 Europe
7.1 Europe Checkpoint Inhibitors for Treating Cancer by Country
7.1.1 Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2016-2021)
7.1.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2016-2021)
7.2 Europe Checkpoint Inhibitors for Treating Cancer Sales by Type
7.3 Europe Checkpoint Inhibitors for Treating Cancer Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa Checkpoint Inhibitors for Treating Cancer by Country
8.1.1 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2016-2021)
8.1.2 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2016-2021)
8.2 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Type
8.3 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Country

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Checkpoint Inhibitors for Treating Cancer Distributors
10.3 Checkpoint Inhibitors for Treating Cancer Customer

11 Global Checkpoint Inhibitors for Treating Cancer Market Forecast
11.1 Global Checkpoint Inhibitors for Treating Cancer Forecast by Region
11.1.1 Global Checkpoint Inhibitors for Treating Cancer Forecast by Regions (2021-2026)
11.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Regions (2021-2026)
11.2 Americas Forecast by Country
11.3 APAC Forecast by Region
11.4 Europe Forecast by Country
11.5 Middle East & Africa Forecast by Country
11.6 Global Checkpoint Inhibitors for Treating Cancer Forecast by Type
11.7 Global Checkpoint Inhibitors for Treating Cancer Forecast by Application

12 Key Players Analysis
12.1 Bristol-Myers Squibb(BMS)
12.1.1 Bristol-Myers Squibb(BMS) Company Information
12.1.2 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product Offered
12.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2019-2021)
12.1.4 Bristol-Myers Squibb(BMS) Main Business Overview
12.1.5 Bristol-Myers Squibb(BMS) Latest Developments
12.2 Merck
12.2.1 Merck Company Information
12.2.2 Merck Checkpoint Inhibitors for Treating Cancer Product Offered
12.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2019-2021)
12.2.4 Merck Main Business Overview
12.2.5 Merck Latest Developments
12.3 Roche
12.3.1 Roche Company Information
12.3.2 Roche Checkpoint Inhibitors for Treating Cancer Product Offered
12.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2019-2021)
12.3.4 Roche Main Business Overview
12.3.5 Roche Latest Developments

13 Research Findings and Conclusion

List of Tables
Table 1. Checkpoint Inhibitors for Treating Cancer Consumption CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of PD-1 Inhibitors
Table 3. Major Players of PD-L1 Inhibitors
Table 4. Major Players of CTLA-4 Inhibitors
Table 5. Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2016-2021) & (g)
Table 6. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2016-2021)
Table 7. Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2016-2021) & ($ million)
Table 8. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type (2016-2021)
Table 9. Global Checkpoint Inhibitors for Treating Cancer Sale Price by Type (2016-2021)
Table 10. Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2016-2021) & (g)
Table 11. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2016-2021)
Table 12. Global Checkpoint Inhibitors for Treating Cancer Value by Application (2016-2021)
Table 13. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2016-2021)
Table 14. Global Checkpoint Inhibitors for Treating Cancer Sale Price by Application (2016-2021)
Table 15. Global Checkpoint Inhibitors for Treating Cancer Sales by Company (2019-2021) & (g)
Table 16. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company (2019-2021)
Table 17. Global Checkpoint Inhibitors for Treating Cancer Revenue by Company (2019-2021) ($ Millions)
Table 18. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Company (2019-2021)
Table 19. Global Checkpoint Inhibitors for Treating Cancer Sale Price by Company (2019-2021)
Table 20. Key Manufacturers Checkpoint Inhibitors for Treating Cancer Producing Area Distribution and Sales Area
Table 21. Players Checkpoint Inhibitors for Treating Cancer Products Offered
Table 22. Checkpoint Inhibitors for Treating Cancer Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Checkpoint Inhibitors for Treating Cancer Sales by Region (2016-2021) (g)
Table 26. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2016-2021)
Table 27. Global Checkpoint Inhibitors for Treating Cancer Revenue by Region (2016-2021) & ($ Millions)
Table 28. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2016-2021)
Table 29. Americas Checkpoint Inhibitors for Treating Cancer Sales by Country (2016-2021) & (g)
Table 30. Americas Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2016-2021)
Table 31. Americas Checkpoint Inhibitors for Treating Cancer Revenue by Country (2016-2021) & ($ Millions)
Table 32. Americas Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2016-2021)
Table 33. Americas Checkpoint Inhibitors for Treating Cancer Sales by Type (2016-2021) & (g)
Table 34. Americas Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2016-2021)
Table 35. Americas Checkpoint Inhibitors for Treating Cancer Sales by Application (2016-2021) & (g)
Table 36. Americas Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2016-2021)
Table 37. APAC Checkpoint Inhibitors for Treating Cancer Sales by Region (2016-2021) & (g)
Table 38. APAC Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2016-2021)
Table 39. APAC Checkpoint Inhibitors for Treating Cancer Revenue by Region (2016-2021) & ($ Millions)
Table 40. APAC Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2016-2021)
Table 41. APAC Checkpoint Inhibitors for Treating Cancer Sales by Type (2016-2021) & (g)
Table 42. APAC Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2016-2021)
Table 43. APAC Checkpoint Inhibitors for Treating Cancer Sales by Application (2016-2021) & (g)
Table 44. APAC Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2016-2021)
Table 45. Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2016-2021) & (g)
Table 46. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2016-2021)
Table 47. Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2016-2021) & ($ Millions)
Table 48. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2016-2021)
Table 49. Europe Checkpoint Inhibitors for Treating Cancer Sales by Type (2016-2021) & (g)
Table 50. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2016-2021)
Table 51. Europe Checkpoint Inhibitors for Treating Cancer Sales by Application (2016-2021) & (g)
Table 52. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2016-2021)
Table 53. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2016-2021) & (g)
Table 54. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2016-2021)
Table 55. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2016-2021) & ($ Millions)
Table 56. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2016-2021)
Table 57. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Type (2016-2021) & (g)
Table 58. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2016-2021)
Table 59. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Application (2016-2021) & (g)
Table 60. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2016-2021)
Table 61. Key and Potential Regions of Checkpoint Inhibitors for Treating Cancer
Table 62. Key Application and Potential Industries of Checkpoint Inhibitors for Treating Cancer
Table 63. Key Challenges of Checkpoint Inhibitors for Treating Cancer
Table 64. Key Trends of Checkpoint Inhibitors for Treating Cancer
Table 65. Checkpoint Inhibitors for Treating Cancer Distributors List
Table 66. Checkpoint Inhibitors for Treating Cancer Customer List
Table 67. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Region (2021-2026) & (g)
Table 68. Global Checkpoint Inhibitors for Treating Cancer Consumption Market Forecast by Region
Table 69. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Region (2021-2026) & ($ millions)
Table 70. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Region (2021-2026)
Table 71. Americas Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2021-2026) & (g)
Table 72. Americas Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Country (2021-2026) & ($ millions)
Table 73. APAC Checkpoint Inhibitors for Treating Cancer Sales Forecast by Region (2021-2026) & (g)
Table 74. APAC Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Region (2021-2026) & ($ millions)
Table 75. Europe Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2021-2026) & (g)
Table 76. Europe Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Country (2021-2026) & ($ millions)
Table 77. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2021-2026) & (g)
Table 78. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Country (2021-2026) & ($ millions)
Table 79. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Type (2021-2026) & (g)
Table 80. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Type (2021-2026)
Table 81. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Type (2021-2026) & ($ Millions)
Table 82. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Type (2021-2026)
Table 83. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application (2021-2026) & (g)
Table 84. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Application (2021-2026)
Table 85. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Application (2021-2026) & ($ Millions)
Table 86. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Application (2021-2026)
Table 87. Bristol-Myers Squibb(BMS) Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 88. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product Offered
Table 89. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales (g), Revenue ($ Million), Price (USD/mg) and Gross Margin (2019-2021E)
Table 90. Bristol-Myers Squibb(BMS) Main Business
Table 91. Bristol-Myers Squibb(BMS) Latest Developments
Table 92. Merck Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 93. Merck Checkpoint Inhibitors for Treating Cancer Product Offered
Table 94. Merck Checkpoint Inhibitors for Treating Cancer Sales (g), Revenue ($ Million), Price (USD/mg) and Gross Margin (2019-2021E)
Table 95. Merck Main Business
Table 96. Merck Latest Developments
Table 97. Roche Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 98. Roche Checkpoint Inhibitors for Treating Cancer Product Offered
Table 99. Roche Checkpoint Inhibitors for Treating Cancer Sales (g), Revenue ($ Million), Price (USD/mg) and Gross Margin (2019-2021E)
Table 100. Roche Main Business
Table 101. Roche Latest Developments
List of Figures
Figure 1. Picture of Checkpoint Inhibitors for Treating Cancer
Figure 2. Checkpoint Inhibitors for Treating Cancer Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2016-2026 (g)
Figure 7. Global Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2016-2026 ($ Millions)
Figure 8. Checkpoint Inhibitors for Treating Cancer Sales by Region (2021 & 2026) & ($ millions)
Figure 9. Product Picture of PD-1 Inhibitors
Figure 10. Product Picture of PD-L1 Inhibitors
Figure 11. Product Picture of CTLA-4 Inhibitors
Figure 12. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2020
Figure 13. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type (2016-2021)
Figure 14. Checkpoint Inhibitors for Treating Cancer Consumed in Melanoma Treatment
Figure 15. Global Checkpoint Inhibitors for Treating Cancer Market: Melanoma Treatment (2016-2021) & (g)
Figure 16. Checkpoint Inhibitors for Treating Cancer Consumed in Bladder Cancer Treatment
Figure 17. Global Checkpoint Inhibitors for Treating Cancer Market: Bladder Cancer Treatment (2016-2021) & (g)
Figure 18. Checkpoint Inhibitors for Treating Cancer Consumed in Other
Figure 19. Global Checkpoint Inhibitors for Treating Cancer Market: Other (2016-2021) & (g)
Figure 20. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2016-2021)
Figure 21. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application in 2020
Figure 22. Checkpoint Inhibitors for Treating Cancer Revenue Market by Company in 2020 ($ Million)
Figure 23. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Company in 2020
Figure 24. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Regions (2016-2021)
Figure 25. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region in 2020
Figure 26. Americas Checkpoint Inhibitors for Treating Cancer Sales 2016-2021 (g)
Figure 27. Americas Checkpoint Inhibitors for Treating Cancer Revenue 2016-2021 ($ Millions)
Figure 28. APAC Checkpoint Inhibitors for Treating Cancer Sales 2016-2021 (g)
Figure 29. APAC Checkpoint Inhibitors for Treating Cancer Revenue 2016-2021 ($ Millions)
Figure 30. Europe Checkpoint Inhibitors for Treating Cancer Sales 2016-2021 (g)
Figure 31. Europe Checkpoint Inhibitors for Treating Cancer Revenue 2016-2021 ($ Millions)
Figure 32. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales 2016-2021 (g)
Figure 33. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Revenue 2016-2021 ($ Millions)
Figure 34. Americas Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2020
Figure 35. Americas Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2020
Figure 36. Americas Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2020
Figure 37. Americas Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2020
Figure 38. United States Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 39. Canada Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 40. Mexico Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 41. Brazil Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 42. APAC Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region in 2020
Figure 43. APAC Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Regions in 2020
Figure 44. APAC Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2020
Figure 45. APAC Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2020
Figure 46. China Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 47. Japan Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 48. Korea Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 49. Southeast Asia Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 50. India Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 51. Australia Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 52. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2020
Figure 53. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2020
Figure 54. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2020
Figure 55. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2020
Figure 56. Germany Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 57. France Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 58. UK Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 59. Italy Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 60. Russia Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 61. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2020
Figure 62. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2020
Figure 63. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2020
Figure 64. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2020
Figure 65. Egypt Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 66. South Africa Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 67. Israel Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 68. Turkey Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 69. GCC Country Checkpoint Inhibitors for Treating Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 70. Channels of Distribution
Figure 71. Distributors Profiles


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界のがん治療用チェックポイント阻害剤市場予測 2021年-2026年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆